# Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia

> **NCT02069886** · PHASE4 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Thalassemia (Transfusion Delendent)

## Interventions

- **DRUG:** deferasirox

## Key facts

- **NCT ID:** NCT02069886
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-12
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02069886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02069886, "Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02069886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*